Trial Profile

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abexinostat (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Head and neck cancer; Malignant melanoma; Mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

20 Mar 2024 Status changed from active, no longer recruiting to completed.
24 May 2022 Planned End Date changed from 31 May 2023 to 30 Nov 2023.
24 May 2022 Planned primary completion date changed from 31 May 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com